Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22
Launched by UNIVERSITY OF VERMONT · Sep 20, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Please contact site for information.
About University Of Vermont
The University of Vermont (UVM) is a leading academic institution known for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UVM leverages its diverse expertise in medicine, public health, and biomedical sciences to conduct cutting-edge clinical studies. The university aims to translate scientific findings into effective treatments and interventions, ultimately improving patient outcomes and contributing to the broader medical community. UVM's research facilities and access to a wide patient population support its mission to foster a culture of inquiry and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Burlington, Vermont, United States
Patients applied
Trial Officials
Warren Bickel, Ph.D.
Principal Investigator
University of Vermont
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials